Correspondence
In Reply
On behalf of all authors I wish to thank both correspondents for their important comments. Because of the word limit of a review article we were not able to discuss in detail all aspects in the main text. We would point out, however, that additional materials are available online and can be downloaded. We explain in particular the possible molecular pathomechanisms and independent effects on the heart—for example, via the sodium-hydrogen-antiporter 1. The web extra material also includes the eFigure that summarizes the effects of gliflozins on different tissues. We think that the mention of the rare adverse effect that is Fournier’s gangrene is very important. We agree that in future—as suggested—the design of registration/licensing studies should be continually optimized. In our view, however, this does not apply specifically to gliflozin research, which is why we did not discuss it in our article.
DOI: 10.3238/arztebl.m2021.0197
On behalf of the authors
Prof. Dr. med. Matthias Laudes
Lehrstuhl für Innere Medizin – Endokrinologie, Diabetologie und klinische Ernährungsmedizin
Universitätsklinikum Schleswig-Holstein
matthias.laudes@uksh.de
Conflict of interest statement
Prof. Laudes received consulting fees from Boehringer, AstraZeneca, and Lilly. He received reimbursement of conference delegate fees and travel expenses, as well as lecture fees, from Lilly and AstraZeneca.
| 1. | Seoudy AK, Schulte DM, Hollstein T, Böhm R, Cascorbi I, Laudes M: Gliflozins for the treatment of congestive heart failure and renal failure in type 2 diabetes. Dtsch Arztebl Int 2021; 118: 122–9 VOLLTEXT |
